Recent studies have focused on the overlap of GLP|GIP|GCGR agonist therapies and dopaminergic communication. While GCGR agonists are commonly employed for addressing type 2 T2DM, their emerging impacts on reinforcement https://harleywfye253657.imblogs.net/90953487/new-glp-activators-and-dopamine-modulation-a-comparative-overview